Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
Subscribe To Our Newsletter & Stay Updated
